SCHEMBL18172376

SCHEMBL18172376

CC(C)(NC(=O)c1cc(-c2ccc(F)cc2)cc(-n2cnnn2)c1)C1CC1.Cc1ccc(-c2cc(C(=O)NC(C)(C)C3CC3)cc(-n3nnnc3C(C)C)c2)cc1

nearest known ligand 0.39

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
P2RX3 P56373 2/20 0.39
P2RX2 Q9UBL9 2/20 0.39
P2RY14 Q15391 4/20 0.35
TSHR P16473 1/20 0.34
PTK2 Q05397 1/20 0.33
MAP3K5 Q99683 2/20 0.33
TDP1 Q9NUW8 1/20 0.33
DPP4 P27487 1/20 0.33
DPP8 Q6V1X1 1/20 0.33
DPP7 Q9UHL4 1/20 0.33
G6PD P11413 1/20 0.33
LMNA P02545 1/20 0.32
POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18172501 0.91 P2RX3 (0.37) P2RX3P2RX2P2RY14MAP3K5LMNA
SCHEMBL18172438 0.90 P2RX3 (0.45) P2RX3P2RX2P2RY14LMNA
SCHEMBL18172427 0.89 P2RX3 (0.40) P2RX3P2RX2P2RY14TSHRPTK2
SCHEMBL18172352 0.86 P2RY14 (0.41) P2RY14TSHRTDP1DPP4DPP8
SCHEMBL20533664 0.82 P2RY14 (0.44) P2RX3P2RX2P2RY14LMNA
SCHEMBL18184305 0.82 P2RX3 (0.37) P2RX3P2RX2P2RY14MAP3K5POLB
SCHEMBL18172450 0.82 P2RY14 (0.43) P2RX3P2RX2P2RY14MAP3K5LMNA
SCHEMBL18172486 0.81 P2RX3 (0.37) P2RX3P2RX2P2RY14TSHRPTK2
SCHEMBL4331537 0.81 P2RX3 (0.49) P2RX3P2RX2P2RY14MAP3K5LMNA
SCHEMBL18706296 0.81 TTK (0.37) P2RX3P2RX2P2RY14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3286182-A1 TETRAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS F. Hoffmann-La Roche AG (CH) 2018-02-28 EP claimed
WO-2016169902-A1 TETRAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2016-10-27 WO claimed